First-In-Human Use Reported for Bioresorbable Efemoral Vascular Scaffold System
New bioresorbable stent aims to improve outcomes for patients with peripheral arterial disease
A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.
December 16, 2020 Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular scaffold system (EVSS) with FlexStep Technology in the EFEMORAL I FIH clinical study. The bioresorbable stent is designed to address a broad range of patients with peripheral arterial disease (PAD), to alleviate symptoms and avoid reintervention for this historically challenging patient population.
Share this article
Share this article
LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the first-in-human (FIH) use of the company s Efemoral
™ Vascular Scaffold System (EVSS) with FlexStep
™ Technology in the EFEMORAL I FIH clinical study. Designed to address a broad range of patients, this innovative technology offers a new approach to treat peripheral arterial disease (PAD), alleviate symptoms, and avoid reintervention for a historically challenging patient population.
The EVSS with FlexStep Technology was specifically developed to address the anatomical challenges and complex biomechanics of patients with symptomatic PAD. The patented FlexStep Technology, through the use of inter-scaffold spaces, combines flexibility with support to accommodate tortuosity and skeletal movement, while the balloon-expandable deployment system easily opens vessels and sustains healthy blood flo